What are the Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) findings of Focal Nodular Hyperplasia (FNH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Focal nodular hyperplasia (FNH) is typically characterized by small, hyperenhancing, and rounded lesions on CT and MRI, which turn isodense/isointense to the surrounding parenchyma in the portal venous phase, with mild T2 iso-to hyperintensity and isointensity in the T1 signal on MRI. The imaging features of FNH can be summarized as follows:

  • On CT, FNH is often identified in the arterial contrast phase as small, hyperenhancing, and rounded lesions that turn isodense to the surrounding parenchyma in the portal venous phase 1.
  • On MRI, FNH-like nodules are commonly homogeneous in attenuation on all series, with mild T2 iso-to hyperintensity, isointensity to slightly diffusion, and isointensity in the T1 signal, and mild or no restricted diffusion 1.
  • After injection of a hepatocyte-specific contrast agent, FNH-like nodules are typically iso-to hyperintense compared to the surrounding parenchyma in the late hepatocyte phase 1.
  • The finding of washout in the delayed phase can also be seen in benign FNH-like nodules, which generally remain stable in size during follow-up and rarely disappear 1. The characteristic imaging features of FNH reflect its pathophysiology, which consists of normal hepatocytes arranged in abnormal architecture with malformed biliary structures and prominent arterial vessels. The hypervascular nature of FNH explains its enhancement pattern, while the fibrous central scar accounts for the delayed enhancement due to slow contrast accumulation in the fibrous tissue.

From the Research

MRI Findings of Focal Nodular Hyperplasia

  • FNH is typically iso- or hypointense on T1-weighted images 2
  • FNH is slightly hyper- or isointense on T2-weighted images 2
  • A hyperintense central scar on T2-weighted images is a characteristic feature of FNH 2, 3
  • FNH demonstrates intense homogeneous enhancement during the arterial phase of gadolinium-enhanced imaging 2
  • Enhancement of the central scar during later phases of gadolinium-enhanced imaging is also a feature of FNH 2

CT Findings of Focal Nodular Hyperplasia

  • FNH frequently shows hypodensity on precontrast CT scans 3
  • Transient immediate enhancement after bolus injection is a common feature of FNH on CT scans 3
  • Homogeneity is a characteristic feature of FNH on CT scans, seen in 85% of cases 3
  • A scar is noted in 31% of FNH cases on CT scans 3

Differential Diagnosis

  • FNH can be distinguished from other hypervascular liver lesions such as hepatocellular adenoma, hepatocellular carcinoma, and hypervascular metastases using MRI and CT findings 2, 3
  • A multimodality approach is essential for the correct diagnosis of FNH to prevent unnecessary surgery 3

Diagnostic Criteria

  • The typical MR triad of isointensity on T1- and/or T2-weighted images, homogeneity, and a scar which shows hyperintensity on T2-WI is seen in only 12% of FNH cases 3
  • Histologic assessment of liver biopsy can record major diagnostic features such as fibrous bands, thick-walled vessels, reactive ductules, and nodularity, which are helpful in diagnosing FNH 4, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2004

Related Questions

What is the best course of action for a 1.2 cm hyperenhancing nodule in the posterior dome of the liver, with differential diagnoses of hemangioma (benign vascular tumor) or focal nodular hyperplasia (FNH)?
What is the preferred diagnostic approach, biopsy or 6-month follow-up imaging, for a 47-year-old asymptomatic female with suspected hepatic fibrosis in the right lobe of the liver, showing abnormal signal and enhancement with mild capsular retraction, but no evidence of focal fluid collection, abscess, or definite mass?
What is the treatment approach for focal nodular hyperplasia (FNH)?
What is the recommended management for focal nodular hyperplasia (FNH)?
What is the recommended approach to surveillance for patients with focal nodular hyperplasia (FNH)?
What are the signs and symptoms of Polymyalgia Rheumatica (PMR)?
What is the diagnosis for a 37-year-old woman, gravida (number of times pregnant) 1, para (number of viable births) 0, at 25 weeks gestation, with sharp, substernal chest pain, worsening with inspiration, and radiating to the right upper quadrant, in the context of a twin pregnancy, thrombocytopenia (low platelet count), and tachycardia (rapid heart rate)?
What are the Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) findings of hepatic adenoma?
What cross-links elastin and what are the resulting products, specifically the role of lysyl oxidase (LOX) in forming desmosine and isodesmosine?
What is the management approach for a 22-year-old primigravida (gravida 1, para 0) at 36 weeks gestation with a history of genital herpes simplex virus (HSV) and no current symptoms or lesions?
What is the diagnosis for a 31-year-old gravida 1 para 0 woman at 8 weeks gestation, conceived through intrauterine insemination (IUI) with donor sperm, presenting with hyperemesis, epigastric pain, and tachycardia, with a history of gastroesophageal reflux disease (GERD) managed with an over-the-counter antacid, and confirmed intrauterine gestation with normal fetal heartbeat on ultrasound?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.